OREANDA-NEWS. According to RIA Novosti, the Russian biotechnology company Biocad is starting to supply Sputnik V vaccine against coronavirus for large-scale vaccination in Russia.

It is reported that Russian President Vladimir Putin at the beginning of December ordered the start of large-scale vaccination against coronavirus infection, primarily providing vaccinations to risk groups.

In fact, "Sputnik V" is the world's first registered vaccine for the prevention of COVID-19, developed by the Gamaleya Research Center for Electrochemistry. The vaccine is based on a well-studied and validated human adenoviral vector platform, the important benefits of which are safety, efficacy and no long-term adverse effects. The drug involves the introduction of two components with an interval of three weeks.

The director of the Gamaleya Center, Alexander Gintsburg, said that post-registration trials of the Sputnik V coronavirus vaccine under the protocol will be completed in May, but the results on effectiveness may already be in January.

Priority vaccination is reported for populations at risk. These are teachers, health workers, social workers. In particular, to date, more than 500 employees of one of the largest medical universities in Russia - the First Moscow State Medical University named after I.M. Sechenov, including the faculty and medical workers of clinical departments.